Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel (ALCOOTAX)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by Institut Curie.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Institut Curie
ClinicalTrials.gov Identifier:
NCT01448759
First received: October 6, 2011
Last updated: October 10, 2011
Last verified: July 2011

October 6, 2011
October 10, 2011
October 2011
October 2012   (final data collection date for primary outcome measure)
Evaluation of plasma alcohol [ Time Frame: One year ] [ Designated as safety issue: No ]
Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel)
Same as current
Complete list of historical versions of study NCT01448759 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion

The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.

In this study, there is no experimental treatment, or experimental care.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Tumors
Other: blood sampling
Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule.
  • Patient with bitherapy are eligible only if the taxane is the first infusion.
  • All type of tumor.
  • Age>18 years old.
  • Signed written informed consent.

Exclusion Criteria:

  • Patient under 18.
  • Patient with bitherapy, if docetaxel or paclitaxel is not administered first.
  • Patient deprived of liberty.
Both
18 Years and older
No
Contact: MARAL Sylvie, UGEC Leader 0156245630 melanie.lebegue@curie.net
France
 
NCT01448759
IC 2011-03
No
Institut Curie
Institut Curie
Not Provided
Principal Investigator: LE TOURNEAU Christophe, MD Institut Curie
Institut Curie
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP